U-NEURON讓再生真正發生釋放羊水幹細胞的再生潛能—從生命起源邁向醫療新境界
Global Leader | Unique in Taiwan
A Multinational Regenerative Medicine Elite Team Building the Future of Amniotic Fluid Stem Cell Therapeutics
Core Regenerative Medicine Platform
Technological Leadership
Holding world-leading patents for amniotic fluid stem cell isolation and culture, U-NEURON focuses on the R&D and application of AFSCs and their derived exosomes. Through proprietary technology platforms and key process integration—from cell sourcing and process scaling to practical translation—we build a core regenerative medicine platform with high scalability and commercial potential.
GTP Certification × GMP Quality Management
Global Standards
Certified by Taiwan TFDA under GTP (Good Tissue Practice) standards, ensuring that cell collection, processing, storage, and transport meet strict safety, quality, and traceability benchmarks. Concurrently, we introduce GMP-level operational frameworks to establish robust exosome manufacturing and quality systems, elevating product consistency, regulatory compliance, global partnership capabilities, and market access.
Long-Term Stability & Traceability
World-Class Biobanking
Utilizing a liquid nitrogen ultra-low temperature storage system (-196°C) paired with smart real-time monitoring to guarantee long-term cell viability and sample stability. Featuring end-to-end traceability, tiered access permissions, and comprehensive documentation certified under ISO 9001 Quality Management Standards, we deliver highly trustworthy cell banking services that meet international specifications.
01
Market Regulatory & Client/Product Application Assessment
Applications: Medical Devices, Cosmetics & Skincare, Dietary Supplements, Pet Care, Regenerative Medicine
Target Markets: Taiwan, Southeast Asia (Malaysia, Singapore, Thailand, Vietnam, Indonesia), Muslim Markets (Middle East)
02
Cell Source Selection & Process Development Assessment
Cell Sources: Human, Animal, Botanical, Probiotic/Microbial, Custom Project Production
Evaluations: Efficacy Assays, Mass Production Feasibility, Estimated Timeline & Cost Analysis
03
Manufacturing, Quality Testing & Downstream Product Manufacturing
Operations: Cell Bank Establishment, Scaled Production, Isolation & Purification, Exosome QC Testing, Bioactivity Assays
Downstream Services: OEM/ODM Contract Manufacturing, Product Efficacy Testing, Regulatory Product Registration & Review
NEWS
U-NEURON Unveils i-ExoCraft® Intelligent Integrated Platform, Ushering Exosomes into a New Era of Design and Foundry Services
Economic Daily News / Reporter Po-Hong Hsieh
Chlitina Holding Partners with U-NEURON to Launch Deer Amniotic Exosome Skincare Series, Surpassing RMB 10 Million in Single-Day Global Debut Sales
Chlitina Holding (4137) has joined forces with U-NEURON (6973) to develop deer amniotic fluid stem cell exosome beauty and skincare products. The companies recently held the grand "CHLITINA Golden Bandage Global Debut Launch Event" in Wuhan, Mainland China, generating single-day launch sales exceeding RMB 10 million! This milestone is expected to further boost revenue for both companies this year.
U-NEURON Launches Exosome R&D Pilot Manufacturing Center, Targeting Healthcare and Wellness Markets
Byline / Photo Credit: Reporter Hsin-Lu Yeh, Photo Center / Hsinchu News Desk
U-NEURON Launches Exosome R&D Pilot Manufacturing Center to Capture Multi-Billion Exosome Market Opportunities
Economic Daily News / Reporter Po-Hong Hsieh
U-NEURON’s Amniotic Fluid Stem Cell New Drug Secures Dual ExpeditedRegulatory Guidance for Regenerative Medicine
U-NEURON (6973-TW) announced today (22nd) that its proprietary new drug candidate UA002, designed for the treatment of erectile dysfunction, has been approved by Taiwan TFDA under the "Project-Based Advisory and Guidance Cases" scheme. Concurrently, UA002 secured the "Flagship Project" (Index Case) qualification from the Center for Drug Evaluation (CDE). Under this dedicated advisory framework, the company expects to accelerate development and regulatory review while mitigating R&D risks, marking dual expeditedregulatory support in the regenerative medicine arena.
U-NEURON Targets Multi-Billion ED Blue Ocean Market, Launching Dual-Engine Growth in Healthcare and Aesthetics
U-NEURON Chairman Dr. Frank Chien Projects Turnaround to Profitability Next Year
Pioneering Patented Amniotic Fluid Stem Cell Technology! Targeting a Multi-Billion-Dollar Market, U-NEURON Chairman States: “Anyone Dissatisfied with Viagra Is Our Customer”
U-NEURON (6973) leverages its world-leading patented amniotic fluid stem cell technology to address the multi-billion-dollar blue ocean market of male erectile dysfunction (ED).
Yonglirong’s revenue/March was 10.56 million yuan, an annual increase of 24.2%, a new high of 26.7 million yuan in the first quarter
Yonglirong (6973) announced on the 7th that its revenue in March 2026 was 10.56 million yuan, an annual increase of 24.25% and a monthly increase of 30.43%; the cumulative first quarter of 2026...
Dual engine assist! Yonglirong’s first-quarter revenue reached 26.7 million yuan, a new high for the same period
Yonglirong (6973)'s consolidated revenue in March reached 10.56 million yuan, a monthly increase of 30.43% and an annual increase of 24.25%; the cumulative first quarter consolidated revenue reached...